IMV

Immunovaccine Inc. ("Immunovaccine" or the "Company") (TSX VENTURE:IMV), a
clinical stage vaccine company, today announced positive results from a
preliminary study of an anti-cocaine vaccine in collaboration with Weill Cornell
Medical College. The vaccine, which added Immunovaccine's DepoVax(TM)
adjuvanting technology to Weill Cornell's novel anti-cocaine vaccine (dAd5GNE),
was being evaluated in rodents for its ability to produce antibodies capable of
blocking cocaine from being delivered to the brain in an effort to prevent its
physiological effect. 


The study showed that the DepoVax-enhanced vaccine produced high levels of
target antibodies that were able to sequester cocaine in the blood of immunized
mice and block its delivery to the brain. Immunovaccine hopes to build on this
interesting proof of concept work and is currently evaluating opportunities to
further develop the program. Further potential studies would aim to confirm
these results and explore the duration of immunity produced by the vaccine.
There are research efforts to develop an anti-cocaine vaccine that is able to
effectively induce and maintain a sufficient immune response without requiring
frequent immunizations. 


"Immunovaccine's delivery system holds the vaccine at the site of injection
allowing the immune system to process the vaccine differently than other
vaccines," said Dr. Marc Mansour, the company's chief science officer. "This
results in strong immunity against the target, in this case cocaine. The next
time cocaine appears in the blood the subject's immune system seizes the
molecules and neutralizes their effect." 


In March 2012, Immunovaccine and Weill Cornell announced a research agreement to
explore the company's technology with a vaccine being developed for treating
cocaine addiction. The project builds on earlier cocaine vaccine work, funded by
the National Institute on Drug Abuse (NIDA) of the National Institutes of Health
(NIH), at Weill Cornell. The goal of this particular study was to evaluate the
ability DepoVax(TM) to trigger a strong immune response with Weill Cornell's
dAd5GNE vaccine. There currently are no anti-cocaine vaccines approved by the
United States Food and Drug Administration (FDA). 


Cocaine abuse is estimated to affect approximately 4.8 million Americans
annually with an additional one million Americans using crack cocaine at least
once each year. A safe and effective anti-cocaine vaccine has the potential to
significantly address the healthcare and societal problem associated with
cocaine abuse and addiction.


About DepoVax

DepoVax(TM)is a patented formulation that provides controlled and prolonged
exposure of antigens plus adjuvant to the immune system, resulting in a strong,
specific and sustained immune response with the capability for single-dose
effectiveness. The DepoVax platform possesses impressive flexibility, allowing
it to work with a broad range of target antigens in various therapeutic
applications. The technology is also commercially scalable, with potential for
years of stability and ease of use in the clinic.


About Immunovaccine

Immunovaccine Inc. applies its novel adjuvanting platform to the development of
vaccines for cancer therapy, infectious diseases and animal health. The
Company's DepoVax(TM) platform is a patented formulation that provides
controlled and prolonged exposure of antigens plus adjuvant to the immune
system. Immunovaccine has advanced two DepoVax-based cancer vaccines into Phase
I human clinical trials. The Company is also advancing a broad infectious
disease pipeline including vaccines in such indications as malaria, respiratory
syncytial virus (RSV) and anthrax. In addition to the Company's human health
vaccine strategy, it continues to capture value from animal health vaccine
applications. Immunovaccine has key partnerships in the animal health sector
including an agreement with Pfizer Animal Health. Connect at www.imvaccine.com.


This press release contains forward-looking information under applicable
securities law. All information that addresses activities or developments that
we expect to occur in the future is forward-looking information. Forward-looking
statements are based on the estimates and opinions of management on the date the
statements are made. However, they should not be regarded as a representation
that any of the plans will be achieved. Actual results may differ materially
from those set forth in this press release due to risks affecting the company,
including access to capital, the successful completion of clinical trials and
receipt of all regulatory approvals. Immunovaccine Inc. assumes no
responsibility to update forward-looking statements in this press release. 


FOR FURTHER INFORMATION PLEASE CONTACT: 
Immunovaccine, Inc.
Dr. Marc Mansour
Chief Science Officer
(902) 492-1819
mmansour@imvaccine.com
www.imvaccine.com


Vida Communication (media)
Tim Brons
(415) 675-7402
tbrons@vidacommunication.com


Vida Communication (investors)
Stephanie Diaz
(415) 675-7401
sdiaz@vidacommunication.com

(TSXV:IMV)
Historical Stock Chart
From Jun 2024 to Jul 2024

(TSXV:IMV)
Historical Stock Chart
From Jul 2023 to Jul 2024